Predictive molecular markers: Has the time come for routine use in lung cancer?

Angela M. Davies, Philip Mack, Primo N Lara, Derick H Lau, Kathleen Danenberg, Paul H. Gumerlock, David R Gandara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Although some evidence exists to support the use of clinical factors such as performance status and weight loss to predict response and toxicity to therapy in non-small cell lung cancer (NSCLC) patients, researchers have shown little prospective data on the use of molecular markers to facilitate selection of specific chemotherapy or new molecularly targeted agents in this patient population. Breast cancer exemplifies the growing role that molecular markers are playing, not only as prognostic factors, but also in predicting response to targeted treatments such as hormonal therapy, and more recently, trastuzumab (Herceptin). Although several studies have examined molecular markers in lung cancer and have shown promising potential value, these studies were retrospective and require prospective validation. To identify molecular markers that reliably predict response and to be able to individualize cytotoxic and targeted therapy for NSCLC patients are the ultimate goals of future trials. This article focuses on a selected number of promising markers under study in lung cancer, including those thought to play roles in response to DNA damaging chemotherapy (excision repair cross-complementing [ERCC1], xeroderma pigmentosum group D [XPD]), taxane resistance ( -tubulin III), antimetabolite therapy (RRM1), irinotecan metabolism (UGT1A1) and epidermal growth factor receptor (EGFR) pathway inhibition. To date, none of these markers can be recommended for routine use in clinical practice.

Original languageEnglish (US)
Pages (from-to)125-131
Number of pages7
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume2
Issue number2
StatePublished - Mar 1 2004

Fingerprint

Lung Neoplasms
irinotecan
Non-Small Cell Lung Carcinoma
Therapeutics
Antimetabolites
Drug Therapy
Xeroderma Pigmentosum
Proxy
Tubulin
Epidermal Growth Factor Receptor
DNA Repair
Weight Loss
Retrospective Studies
Research Personnel
Breast Neoplasms
DNA
Population
Trastuzumab

Keywords

  • Chemotherapy
  • Cisplatin
  • EGFR
  • Epidermal growth factor receptor inhibitors
  • ERCC1
  • Gemcitabine
  • Irinotecan
  • Molecular markers
  • Non-small cell lung cancer
  • RRM1
  • Taxanes
  • Trastuzumab
  • UGT1A1
  • XRCC1

ASJC Scopus subject areas

  • Oncology

Cite this

Predictive molecular markers : Has the time come for routine use in lung cancer? / Davies, Angela M.; Mack, Philip; Lara, Primo N; Lau, Derick H; Danenberg, Kathleen; Gumerlock, Paul H.; Gandara, David R.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 2, No. 2, 01.03.2004, p. 125-131.

Research output: Contribution to journalArticle

@article{a4af2ba3a31c4970a9d9928e8cab6f7c,
title = "Predictive molecular markers: Has the time come for routine use in lung cancer?",
abstract = "Although some evidence exists to support the use of clinical factors such as performance status and weight loss to predict response and toxicity to therapy in non-small cell lung cancer (NSCLC) patients, researchers have shown little prospective data on the use of molecular markers to facilitate selection of specific chemotherapy or new molecularly targeted agents in this patient population. Breast cancer exemplifies the growing role that molecular markers are playing, not only as prognostic factors, but also in predicting response to targeted treatments such as hormonal therapy, and more recently, trastuzumab (Herceptin). Although several studies have examined molecular markers in lung cancer and have shown promising potential value, these studies were retrospective and require prospective validation. To identify molecular markers that reliably predict response and to be able to individualize cytotoxic and targeted therapy for NSCLC patients are the ultimate goals of future trials. This article focuses on a selected number of promising markers under study in lung cancer, including those thought to play roles in response to DNA damaging chemotherapy (excision repair cross-complementing [ERCC1], xeroderma pigmentosum group D [XPD]), taxane resistance ( -tubulin III), antimetabolite therapy (RRM1), irinotecan metabolism (UGT1A1) and epidermal growth factor receptor (EGFR) pathway inhibition. To date, none of these markers can be recommended for routine use in clinical practice.",
keywords = "Chemotherapy, Cisplatin, EGFR, Epidermal growth factor receptor inhibitors, ERCC1, Gemcitabine, Irinotecan, Molecular markers, Non-small cell lung cancer, RRM1, Taxanes, Trastuzumab, UGT1A1, XRCC1",
author = "Davies, {Angela M.} and Philip Mack and Lara, {Primo N} and Lau, {Derick H} and Kathleen Danenberg and Gumerlock, {Paul H.} and Gandara, {David R}",
year = "2004",
month = "3",
day = "1",
language = "English (US)",
volume = "2",
pages = "125--131",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "2",

}

TY - JOUR

T1 - Predictive molecular markers

T2 - Has the time come for routine use in lung cancer?

AU - Davies, Angela M.

AU - Mack, Philip

AU - Lara, Primo N

AU - Lau, Derick H

AU - Danenberg, Kathleen

AU - Gumerlock, Paul H.

AU - Gandara, David R

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Although some evidence exists to support the use of clinical factors such as performance status and weight loss to predict response and toxicity to therapy in non-small cell lung cancer (NSCLC) patients, researchers have shown little prospective data on the use of molecular markers to facilitate selection of specific chemotherapy or new molecularly targeted agents in this patient population. Breast cancer exemplifies the growing role that molecular markers are playing, not only as prognostic factors, but also in predicting response to targeted treatments such as hormonal therapy, and more recently, trastuzumab (Herceptin). Although several studies have examined molecular markers in lung cancer and have shown promising potential value, these studies were retrospective and require prospective validation. To identify molecular markers that reliably predict response and to be able to individualize cytotoxic and targeted therapy for NSCLC patients are the ultimate goals of future trials. This article focuses on a selected number of promising markers under study in lung cancer, including those thought to play roles in response to DNA damaging chemotherapy (excision repair cross-complementing [ERCC1], xeroderma pigmentosum group D [XPD]), taxane resistance ( -tubulin III), antimetabolite therapy (RRM1), irinotecan metabolism (UGT1A1) and epidermal growth factor receptor (EGFR) pathway inhibition. To date, none of these markers can be recommended for routine use in clinical practice.

AB - Although some evidence exists to support the use of clinical factors such as performance status and weight loss to predict response and toxicity to therapy in non-small cell lung cancer (NSCLC) patients, researchers have shown little prospective data on the use of molecular markers to facilitate selection of specific chemotherapy or new molecularly targeted agents in this patient population. Breast cancer exemplifies the growing role that molecular markers are playing, not only as prognostic factors, but also in predicting response to targeted treatments such as hormonal therapy, and more recently, trastuzumab (Herceptin). Although several studies have examined molecular markers in lung cancer and have shown promising potential value, these studies were retrospective and require prospective validation. To identify molecular markers that reliably predict response and to be able to individualize cytotoxic and targeted therapy for NSCLC patients are the ultimate goals of future trials. This article focuses on a selected number of promising markers under study in lung cancer, including those thought to play roles in response to DNA damaging chemotherapy (excision repair cross-complementing [ERCC1], xeroderma pigmentosum group D [XPD]), taxane resistance ( -tubulin III), antimetabolite therapy (RRM1), irinotecan metabolism (UGT1A1) and epidermal growth factor receptor (EGFR) pathway inhibition. To date, none of these markers can be recommended for routine use in clinical practice.

KW - Chemotherapy

KW - Cisplatin

KW - EGFR

KW - Epidermal growth factor receptor inhibitors

KW - ERCC1

KW - Gemcitabine

KW - Irinotecan

KW - Molecular markers

KW - Non-small cell lung cancer

KW - RRM1

KW - Taxanes

KW - Trastuzumab

KW - UGT1A1

KW - XRCC1

UR - http://www.scopus.com/inward/record.url?scp=79959317098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959317098&partnerID=8YFLogxK

M3 - Article

C2 - 19777702

AN - SCOPUS:79959317098

VL - 2

SP - 125

EP - 131

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 2

ER -